PLEOPHARMA, INC. REPORTS POSITIVE PHASE 2b CLINICAL TRIAL DATA FOR MITIGATION OF CANNABIS WITHDRAWAL: A POTENTIAL FIRST IN CLASS TREATMENT

Phase 2b Study for PP-01 Met Its Primary Endpoint End of Phase 2 Meeting with FDA Completed Phase 3 Preparations Underway PHOENIXVILLE, Pa., Sept. 5, 2024 /PRNewswire/ — PleoPharma, Inc., a privately held company focused on cannabis related health issues, announced today Phase 2b study…